Literature DB >> 10837251

Cyclic AMP regulates the HERG K(+) channel by dual pathways.

J Cui1, Y Melman, E Palma, G I Fishman, T V McDonald.   

Abstract

Lethal cardiac arrhythmias are a hallmark of the hereditary Long QT syndrome (LQTS), a disease produced by mutations of cardiac ion channels [1]. Often these arrhythmias are stress-induced, suggesting a relationship between beta-adrenergic activation of adenylate cyclase and cAMP-dependent alteration of one or more of the ion channels involved in LQTS. Second messengers modulate ion channel activity either by direct interaction or through intermediary kinases and phosphatases. Here we show that the second messenger cAMP regulates the K(+) channel mutated in the LQT2 form of LQTS, HERG [2], both directly and indirectly. Activation of cAMP-dependent protein kinase (PKA) causes phosphorylation of HERG accompanied by a rapid reduction in current amplitude, acceleration of voltage-dependent deactivation, and depolarizing shift in voltage-dependent activation. In a parallel pathway, cAMP directly binds to the HERG protein with the opposing effect of a hyperpolarizing shift in voltage-dependent activation. The summation of cAMP-mediated effects is a net diminution of the effective current, but when HERG is complexed with with the K(+) channel accessory proteins MiRP1 or minK, the stimulatory effects of cAMP are favored. These findings provide a direct link between stress and arrhythmia by a unique mechanism where a single second messenger exerts complex regulation of an ion channel via two distinct pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837251     DOI: 10.1016/s0960-9822(00)00516-9

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  46 in total

1.  Functional characterization of the C-terminus of the human ether-à-go-go-related gene K(+) channel (HERG).

Authors:  E Aydar; C Palmer
Journal:  J Physiol       Date:  2001-07-01       Impact factor: 5.182

2.  14-3-3 amplifies and prolongs adrenergic stimulation of HERG K+ channel activity.

Authors:  Anna Kagan; Yonathan F Melman; Andrew Krumerman; Thomas V McDonald
Journal:  EMBO J       Date:  2002-04-15       Impact factor: 11.598

3.  Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia.

Authors:  Fang Zheng; Huiyu Li; Kaiwei Liang; Yimei Du; Dongmei Guo; Shiang Huang
Journal:  Med Oncol       Date:  2011-12-10       Impact factor: 3.064

4.  Differential regulation of the slow and rapid components of guinea-pig cardiac delayed rectifier K+ channels by hypoxia.

Authors:  Livia C Hool
Journal:  J Physiol       Date:  2003-11-21       Impact factor: 5.182

5.  Triggering of cardiac arrhythmic events in long QT syndrome: lessons from funny bunnies.

Authors:  Chia Tung Wu; Stanley Nattel
Journal:  J Physiol       Date:  2012-03-15       Impact factor: 5.182

Review 6.  HERG1 channelopathies.

Authors:  Michael C Sanguinetti
Journal:  Pflugers Arch       Date:  2009-11-22       Impact factor: 3.657

7.  Partially dominant mutant channel defect corresponding with intermediate LQT2 phenotype.

Authors:  Yamini Krishnan; Renjian Zheng; Christine Walsh; Yingying Tang; Thomas V McDonald
Journal:  Pacing Clin Electrophysiol       Date:  2011-09-25       Impact factor: 1.976

8.  HERG biosynthesis: the positive influence of negative charge.

Authors:  Geoffrey W Abbott; Torsten K Roepke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

9.  PKA phosphorylation of HERG protein regulates the rate of channel synthesis.

Authors:  Jian Chen; Jakub Sroubek; Yamini Krishnan; Yan Li; Jinsong Bian; Thomas V McDonald
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-20       Impact factor: 4.733

10.  Ether-à-gogo-related gene (erg1) potassium channels shape the dark response of horizontal cells in the mammalian retina.

Authors:  Andreas Feigenspan; Jennifer Trümpler; Petra Dirks; Reto Weiler
Journal:  Pflugers Arch       Date:  2008-11-08       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.